SPPI - Spectrum Pharmaceuticals: Rolontis Korean Facility Inspection Presents Opportunity
- Rolontis approval was delayed due to Covid-19 and the FDA's inability to inspect its Korean manufacturing facility.
- The FDA plans to inspect the Hanmi facility this month.
- That should be an opportunity for a quick investment.
For further details see:
Spectrum Pharmaceuticals: Rolontis Korean Facility Inspection Presents Opportunity